Status:
COMPLETED
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Candidiasis, Esophageal
Candidiasis, Invasive
Eligibility:
All Genders
3-17 years
Phase:
PHASE2
Brief Summary
The study estimates the safety, efficacy, and pharmacokinetics of caspofungin (MK-0991) in Japanese children and adolescents with documented Candida or Aspergillus infections.
Eligibility Criteria
Inclusion
- Japanese patients in whom a causative fungus is detected before treatment with the study drug or patients with strongly suspected deep-seated fungal infection due to Candida species (spp.) or Aspergillus spp.
Exclusion
- Patients with mycoses other than ones due to Candida spp. or Aspergillus spp.
- Patients who will receive other systemic antifungal agents for the first time in screening period
Key Trial Info
Start Date :
July 6 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 17 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01165320
Start Date
July 6 2010
End Date
September 17 2013
Last Update
August 27 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.